Home / 2018 / February (page 5)

Monthly Archives: February 2018

Feb. 10, 2018

As I was driving home the other night I heard a duet by Bette Midler and Barbra Streisand. The lyrics included “Anything you can do, I can do better; I can do anything better than you.” For some reason this got me thinking about the use of AI (artificial intelligence). …

Read More »

Point-Counterpoint, Part 1: How to Overcome the Complexities of Treatment Decisions for Your Patients with Type 2 Diabetes

In the last four issues, we discussed a new software that can go through over 6 million possible treatments using anywhere from 1 to 5 drugs for an effective treatment for type 2 diabetes. Along with determining the best treatment for the patient, it includes the ability to put in what the patient can afford in their budget. Dr. John Interlandi, one of our readers, has submitted a counterpoint to using this software to decide the best treatment options. In Part 1, Dr. Interlandi shares his concerns about the use of AI in medical decision making. 

Read More »

Treatment Cost

How does cost play in your determination for treatment? Follow the link to see how you and your colleagues compare.

Read More »

Avoiding Heart Risk

A 68-year-old male presents to your office for a follow-up visit. His past medical history is significant for a myocardial infarction (five years ago) and he has type 2 diabetes. His current medications include an ACE inhibitor, a statin, aspirin, and metformin. Despite good compliance with his medications and beneficial lifestyle changes, he is not able to achieve his individualized target A1C of 7.5-8%. You decide it would be beneficial to add a second antihyperglycemic agent. Which of the following medications should be avoided due to CVD risk? A.Pioglitazone B. Exenatide C. Rosiglitazone D. Sitaglipitin E. None of the above Follow the link for the answer.

Read More »

Ronald Swerdloff Current Interview

Dr. Ronald S. Swerdloff graduated with his BS from UCLA/UCB in 1959 and an MDvin 1962 from UCSF. He began his clinical training at the University of Washington, only to be drafted and expected to serve as a medical officer in the Vietnam war. Instead he was assigned to a brilliant physician scientist at the NIH and finally finished his training back at UCLA. Dr. Swerdloff has been a leader in reproductive endocrinology for the last four decades, including pubertal development, male contraception, androgen physiology and modeling, androgen drug development and hormones in aging.

Read More »